Multistage phase II design for mixed tumor response and time-to-event endpoints: An application for screening new drugs in hepatocellular carcinoma (HCC).

被引：0
|
作者：
Zee, Benny C. Y.
Lai, Xin
Lee, Ann Sing
Lai, Maria
Chong, Marc
Kwok, Chloe
Jolivet, Jacques
机构：
[1] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
[2] Tuen Mun Hosp, Tuen Mun, Hong Kong, Peoples R China
[3] Aegera Therapeut Pharmascience Inc, Montreal, PQ, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14706
引用
收藏
页数：1
相关论文
共 9 条
  • [1] Mixed response and time-to-event endpoints for multistage single-arm phase II design
    Xin Lai
    Benny Chung-Ying Zee
    [J]. Trials, 16
  • [2] Mixed response and time-to-event endpoints for multistage single-arm phase II design
    Lai, Xin
    Zee, Benny Chung-Ying
    [J]. TRIALS, 2015, 16
  • [3] A new randomized phase II design for testing investigational drugs in hepatocellular carcinoma (HCC).
    Zee, BC
    Mok, TS
    Yeo, W
    Chan, ATC
    Johnson, PJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 364S - 364S
  • [4] Bayesian enhancement two-stage design for single-arm phase II clinical trials with binary and time-to-event endpoints
    Shi, Haolun
    Yin, Guosheng
    [J]. BIOMETRICS, 2018, 74 (03) : 1055 - 1064
  • [5] BILITE: A Bayesian randomized phase II design for immunotherapy by jointly modeling the longitudinal immune response and time-to-event efficacy
    Guo, Beibei
    Zang, Yong
    [J]. STATISTICS IN MEDICINE, 2020, 39 (29) : 4439 - 4451
  • [6] Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced Hepatocellular Carcinoma (HCC)
    Waidmann, O.
    Merle, P.
    Rimassa, L.
    Ryoo, B-Y
    Cicin, I
    Harris, W. P.
    Nemunaitis, J.
    Olteanu, S.
    Sarker, D.
    Tan, B. R.
    Van Vlierberghe, H.
    Sen, S.
    Love, C.
    Cheng, A-L
    El-Khoueiry, A. B.
    Meyer, T.
    Kelley, R. K.
    Abou-Alfa, G. K.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 283 - 284
  • [7] Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC)
    Merle, P.
    Rimassa, L.
    Ryoo, B.
    Cicin, I.
    Harris, W.
    Banu, E.
    Sarker, D.
    Tan, B.
    Van Vlierberghe, H.
    Sen, S.
    Love, C.
    Cheng, A.
    Meyer, T.
    Kelley, R.
    Abou-Alfa, G.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 104 - 104
  • [8] Time to Progression (TTP) and Response Rate (RR) Are Not Reliable Surrogate Endpoints for Overall Survival (OS) in Hepatocellular Carcinoma (HCC): An Analysis from the Phase 3 RESORCE Trial
    Bruix, Jordi
    Huang, Liping
    Nakajima, Keiko
    Han, Guohong
    Meinhardt, Gerold
    Merle, Philippe
    [J]. HEPATOLOGY, 2018, 68 : 169A - 169A
  • [9] Assessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Yau, T.
    Merle, P.
    Rimassa, L.
    Ryoo, B-Y.
    Cicin, I.
    Harris, W. P.
    Banu, E.
    Sarker, D.
    Tan, B.
    van Vlierberghe, H.
    Sen, S.
    Love, C.
    Cheng, A-L.
    Meyer, T.
    Kelley, R. K.
    Abou-Alfa, G. K.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
1